文献速递心脑血管急症

卵圆孔未闭封堵术与药物治疗对卒中后长期结局的比较

Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke.
PubMed 文献 · N Engl J Med · 2017-01-01
一句话结论隐源性缺血性卒中合并卵圆孔未闭的18至60岁患者,延长随访中封堵术较单纯药物治疗降低复发性缺血性卒中发生率(HR 0.55)。

该多中心、随机、开放标签、终点事件盲法判定的试验纳入980例18至60岁卵圆孔未闭合并隐源性缺血性卒中患者,随机接受卵圆孔未闭封堵术或单纯药物治疗(阿司匹林、华法林、氯吡格雷或阿司匹林联合缓释双嘧达莫)。中位随访5.9年,封堵组复发性缺血性卒中发生率为0.58例/100患者年,药物组为1.07例/100患者年(HR 0.55,95%CI 0.31至0.999,P=0.046)。原因未明的复发性缺血性卒中在封堵组为10例,药物组为23例(HR 0.38,95%CI 0.18至0.79,P=0.007)。封堵组静脉血栓栓塞更常见。

要点

  • 18至60岁卵圆孔未闭合并隐源性缺血性卒中患者,封堵术组复发性缺血性卒中0.58例/100患者年 vs 药物组1.07例/100患者年(HR 0.55,95%CI 0.31至0.999,P=0.046)。
  • 原因未明的复发性缺血性卒中封堵组10例 vs 药物组23例(HR 0.38,95%CI 0.18至0.79,P=0.007)。
  • 封堵组静脉血栓栓塞(包括肺栓塞和深静脉血栓)比药物组更常见。
  • 两组治疗暴露不等(封堵组3141患者年 vs 药物组2669患者年),因药物组脱落率更高。
  • 延长随访期数据分析被认定为探索性。

适用人群与场景

  • 18至60岁、卵圆孔未闭、曾发生隐源性缺血性卒中的患者。
  • 多中心、随机、开放标签试验,共69个研究中心,纳入980例患者(平均年龄45.9岁)。

处置流程与药物剂量

  • 卵圆孔未闭封堵组接受卵圆孔未闭封堵术。
  • 药物治疗组接受阿司匹林、华法林、氯吡格雷或阿司匹林联合缓释双嘧达莫。

研究设计与关键结果

  • 多中心、随机、开放标签、终点事件盲法判定的试验,纳入980例患者(平均年龄45.9岁),69个研究中心,中位随访5.9年。
  • 主要疗效终点为复发性非致死性缺血性卒中、致死性缺血性卒中或随机化后早期死亡的复合终点。
  • 意向治疗人群中,复发性缺血性卒中封堵组18例 vs 药物组28例,发生率分别为0.58例/100患者年 vs 1.07例/100患者年(HR 0.55,95%CI 0.31至0.999,P=0.046,log-rank检验)。
  • 原因未明的复发性缺血性卒中封堵组10例 vs 药物组23例(HR 0.38,95%CI 0.18至0.79,P=0.007)。
  • 静脉血栓栓塞(包括肺栓塞和深静脉血栓)在封堵组比药物组更常见。
  • 治疗暴露不等:封堵组3141患者年 vs 药物组2669患者年,因药物组脱落率更高。
  • 延长随访期数据分析被认定为探索性。

证据类型、等级与局限

  • 证据类型:多中心、随机、开放标签试验,终点事件盲法判定。
  • 延长随访期数据分析被认定为探索性。
  • 局限:延长随访期数据分析被认定为探索性;两组治疗暴露不等(封堵组3141患者年 vs 药物组2669患者年),因药物组脱落率更高。

对床旁实践的改变

  • 对于18至60岁卵圆孔未闭合并隐源性缺血性卒中患者,延长随访中卵圆孔未闭封堵术与单纯药物治疗相比复发性缺血性卒中发生率更低(HR 0.55)。
  • 封堵组静脉血栓栓塞(包括肺栓塞和深静脉血栓)比药物组更常见。
  • 当前延长随访期数据分析被认定为探索性,原试验期主要结局分析结果已另文报告。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Whether closure of a patent foramen ovale reduces the risk of recurrence of ischemic stroke in patients who have had a cryptogenic ischemic stroke is unknown.

METHODS: In a multicenter, randomized, open-label trial, with blinded adjudication of end-point events, we randomly assigned patients 18 to 60 years of age who had a patent foramen ovale (PFO) and had had a cryptogenic ischemic stroke to undergo closure of the PFO (PFO closure group) or to receive medical therapy alone (aspirin, warfarin, clopidogrel, or aspirin combined with extended-release dipyridamole; medical-therapy group). The primary efficacy end point was a composite of recurrent nonfatal ischemic stroke, fatal ischemic stroke, or early death after randomization. The results of the analysis of the primary outcome from the original trial period have been reported previously; the current analysis of data from the extended follow-up period was considered to be exploratory.

RESULTS: We enrolled 980 patients (mean age, 45.9 years) at 69 sites. Patients were followed for a median of 5.9 years. Treatment exposure in the two groups was unequal (3141 patient-years in the PFO closure group vs. 2669 patient-years in the medical-therapy group), owing to a higher dropout rate in the medical-therapy group. In the intention-to-treat population, recurrent ischemic stroke occurred in 18 patients in the PFO closure group and in 28 patients in the medical-therapy group, resulting in rates of 0.58 events per 100 patient-years and 1.07 events per 100 patient-years, respectively (hazard ratio with PFO closure vs. medical therapy, 0.55; 95% confidence interval [CI], 0.31 to 0.999; P=0.046 by the log-rank test). Recurrent ischemic stroke of undetermined cause occurred in 10 patients in the PFO closure group and in 23 patients in the medical-therapy group (hazard ratio, 0.38; 95% CI, 0.18 to 0.79; P=0.007). Venous thromboembolism (which comprised events of pulmonary embolism and deep-vein thrombosis) was more common in the PFO closure group than in the medical-therapy group.

CONCLUSIONS: Among adults who had had a cryptogenic ischemic stroke, closure of a PFO was associated with a lower rate of recurrent ischemic strokes than medical therapy alone during extended follow-up. (Funded by St. Jude Medical; RESPECT ClinicalTrials.gov number, NCT00465270 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Saver JL, Carroll JD, Thaler DE, et al. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. N Engl J Med. 2017. PMID: 28902590. doi:10.1056/NEJMoa1610057

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。